Antimicrobial resistance is a major public health problem globally. Likewise, forms of
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …

Background Bedaquiline and delamanid are the first drugs of new classes registered for
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …

Simple Summary The incidence and developing status of multidrug-resistant bacteria and
fungi, as well as their related mortality, is reviewed by a systematic published literature …

Background Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an
obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens …

Rationale: Bedaquiline and delamanid offer the possibility of more effective and less toxic
treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however …

Background Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-
drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially …

Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis
(MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment …

BACKGROUND: Evidence of the effectiveness of the WHO-recommended design of longer
individualized regimens for multidrug-or rifampicin-resistant TB (MDR/RR-TB) is limited …

Tuberculosis (TB) treatment relies primarily on 70-year-old drugs, and prophylaxis suffers
from the lack of an effective vaccine. Among the 10 million people exhibiting disease …